Finland· FI-REL-REL5922
Gestapuran
A medroxyprogesterone product, registered in Finland by Schering Oy. The same ATC class is registered in 8 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Medroxyprogesterone is registered in 8 of 19 countries.
Countries holding a registration under ATC L02AB02 (medroxyprogesterone), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 6 of them publish a price we can compare per daily dose
Medroxyprogesterone · ATC L02AB02
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of medroxyprogesterone costs, country by country.
Normalised to the WHO defined daily dose (1 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Medroxyprogesterone · price per daily dose (1 g)
USD · FX 28 Sept 2026
- CH Switzerland$5.69
The record
At a glance
Fimea (Finland)- Manufacturer
- Schering Oy
- Country
- Finland (FI)
- ATC code
- L02AB02
- ATC class
- Medroxyprogesterone
- Defined daily dose
- 1 g, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
241 interactions on record for medroxyprogesterone.
Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Medroxyprogesterone · interactions on record
241 records
- 21 severe
- 213 moderate
- 7 minor
Most severe, free to view
- Tranexamic acidB02AA02severe
- BosentanC02KX01severe
- GriseofulvinD01AA08severe
- GriseofulvinD01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L02AB02
Medroxyprogesterone, as other registers publish it.
- PolandDepo-ProveraPfizer Europe MA EEIG
- CzechiaDEPO-PROVERAPfizer, spol. s r.o., Praha
- CzechiaDEPO-PROVERAPfizer, spol. s r.o., Praha
- CzechiaDEPO-PROVERAPfizer, spol. s r.o., Praha
- CzechiaDEPO-PROVERAPfizer, spol. s r.o., Praha
- FinlandFarlutalPharmacia Oy
- FinlandFarlutalParanova Oy
- FinlandFarlutalPharmacia & Upjohn S.P.A.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f64e72b0-d06c-4cb4-8b47-f5107f7cf981 GET /v1/drugs/f64e72b0-d06c-4cb4-8b47-f5107f7cf981?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "1",
"form": "tabletti",
"route": null,
"ddd_unit": "g",
"strength": "50 mg",
"atc_label": "medroksiprogesteroni",
"ma_number": "5876",
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": null,
"fimea_rel_id": "REL5922",
"authorised_at": "1969-09-17"
}See everything about medroxyprogesterone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.